



American
Heart
Association.



AMERICAN
COLLEGE of
CARDIOLOGY®

2023 AHA/ACC Clinical Performance and Quality Measures for Coronary Artery Revascularization

Coronary Artery Revascularization Performance Measure Writing Committee Chairs:

Gregory J. Dehmer, MD, MACC, MSCAI, FAHA, *Chair*

Cindy L. Grines, MD, MSCAI, FACC, *Vice Chair*

AHA/ACC Joint Staff:

Abdul R. Abdullah, MD, *National Director, Guideline Science*

Rebecca L. Diekemper, MPH, *Science and Health Advisor, Performance Measures*

Revascularization Performance Measures Writing Committee

- In 2022, a 15-member writing committee was convened to develop a measure set addressing coronary artery revascularization.
- The writing committee was charged with developing new measures to evaluate the use of coronary artery revascularization in accordance with the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization.”

| | |
|---|--|
| Gregory J. Dehmer, MD, MACC, MSCAI, FAHA, Chair | |
| Cindy L. Grines, MD, MSCAI, FACC, Vice Chair | |
| Faisal G. Bakaeen, MD | Jennifer Frampton, DO, MPH |
| Dorian L. Beasley, MD, FACC | Connie N. Hess, MD, MHS, FACC, FAHA, FSCAI |
| Theresa M. Beckie, PhD, MN, RN, FAHA | Nkechinyere Ijioma, MBBS, FACC, FAHA |
| Jack Boyd, MD | Jennifer S. Lawton, MD, FAHA |
| Joaquin E. Cigarroa, MD, FACC, MSCAI | Binita Shah, MD, MS, FACC, FSCAI |
| Sandeep R. Das, MD, MPH, FACC, FAHA | Nadia R. Sutton, MD, MPH, FACC, FSCAI |
| Rebecca L. Diekemper, MPH | |

Top 10 Take-Home Messages

1. This document describes performance measures for coronary revascularization that are appropriate for public reporting or pay-for-performance programs.
2. This is the first joint American Heart Association/American College of Cardiology document developing measures related to coronary artery revascularization.
3. Most performance measures were developed from the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization” and are selected from the strongest recommendations (Class 1 or 3).
4. Quality measures are included as metrics that may be useful for local quality improvement programs but are not yet appropriate for public reporting or pay-for-performance programs.
5. Structural measures are useful to assess infrastructure, systems, and processes of care. Two structural measures were developed. One structural measure is related to the presence and function of the Heart Team and the other structural measure is related to registry participation.

Top 10 Take-Home Messages (Continued)

6. For all measures, if the clinician determines the guideline-recommended care is inappropriate for the patient, that patient is excluded from the measure.
7. For all measures, patients who decline treatment or care are excluded.
8. Where possible, these measures were aligned with those developed by other organizations such as the National Quality Forum, Centers for Medicare & Medicaid Services, and the Society of Thoracic Surgeons.
9. Performance measurement sets serve as vehicles to accelerate translation of scientific evidence into clinical practice and are intended to provide practitioners and institutions with tools to measure the quality of care provided and identify opportunities for improvement.
10. Coronary artery revascularization is not static but continues to evolve as new techniques, therapies, and treatment strategies emerge, which will require ongoing review and revision of these measures.



American
Heart
Association®



AMERICAN
COLLEGE of
CARDIOLOGY®

Changes to Existing Measures

Retired Measures

Select measures from the 2013 performance measures for adults undergoing PCI measure set were retired

| Measure No. | Care Setting | Measure Title | Rationale for Retiring the Measure |
|-------------|-----------------------|---|--|
| 1 | Outpatient, Inpatient | Comprehensive Documentations of Indications for PCI | Captured in EHRs and national databases, but there is subjectivity in the description of symptoms that could affect the indications for PCI. |
| 2 | Inpatient, Outpatient | Appropriate Indication for Elective PCI | High rate of capture in EHRs and national databases; included in SDM and informed consent. |
| 3 | Inpatient, Outpatient | Assessment of Candidacy for Dual-Antiplatelet Therapy | Outdated; more detailed recommendations exist for different circumstances. |
| 4 | Inpatient, Outpatient | Use of Embolic Protection Devices in the Treatment of Saphenous Vein Bypass Graft Disease | No longer Class 1 recommendation; now Class 2a, LOE B-R in 2021 Coronary artery revascularization guideline. |
| 5 | Inpatient, Outpatient | Documentation of Preprocedural Glomerular Filtration Rate and Contrast Dose Used During the Procedure | No longer in guidelines; moved to table of best practices. |
| 6 | Inpatient, Outpatient | Radiation Dose Documentation | Now required by federal agencies. |
| 7 | Inpatient, Outpatient | Postprocedural Optimal Medical Therapy Composite | Optimal medical therapy is difficult to define; variable among individual patients. |
| 10 | Inpatient, Outpatient | Annual Operator PCI Volume | Relationship between volume and outcomes is controversial and debated. |
| 11 | Inpatient, Outpatient | Annual Hospital PCI Volume | Relationship between volume and outcomes is controversial and debated. |

Revised Measures

Select measures from the 2018 cardiac rehabilitation measure set and the 2013 performance measures for adults undergoing PCI were revised

| Measure No. | Measure Title | Description of Revision | Rationale for Revision |
|--|---|--|---|
| PM-1 and PM-3 (from the 2018 cardiac rehabilitation measure set) | Cardiac Rehabilitation Patient Referral | Separate recommendation for referral from inpatient and outpatient settings. | Most current recommendations used. |
| Measure 9 (from the 2013 performance measures for adults undergoing PCI) | Regional or National PCI Registry Participation | Participation from NCDR, STS, VA CART, or other regional or national databases included. | Expanded measure to include both PCI and CABG data. |



American
Heart
Association.



AMERICAN
COLLEGE of
CARDIOLOGY®

Summary of Performance, Quality, and Structural Measures

For Coronary Artery Revascularization

Performance Measures

- Developed from Class 1 class of recommendation (COR) and Level A and B level of evidence (LOE) (i.e., strong recommendations based on the highest quality of evidence).
- Designed to be considered for use in national quality payment and reporting programs by entities such as the Centers for Medicare & Medicaid Services (CMS) and the National Committee for Quality Assurance (NCQA).

Quality Measures

- Based on lower ranges of CORs and LOEs.
- Designed to support quality improvement initiatives and activities at the national or microsystem levels.

Structural Measures

- Designed to evaluate the capability and capacity of various levels of the US healthcare system to implement recommended strategies from Clinical Practice Guidelines, such as standardized protocols, electronic health record surveillance, telehealth, team-based care, a single plan of care, and performance measurement.
- Intended for qualitative evaluation of process and infrastructure for these strategies at the care delivery unit (CDU) level (including solo/small physician offices, group practices, health systems, public health sites, accountable care organizations, and clinically integrated networks).

Performance Measures

| Measure No. | Measure Title/Description | COR/LOE |
|----------------------|--|-------------------------------------|
| Performance Measures | | |
| PM-1 | Use of Coronary Physiology | COR: 1, LOE: A |
| PM-2 | DAPT Use With PCI | COR: 1, LOE: B-R; COR: 1, LOE: C-LD |
| PM-3 | Antiplatelets and Anticoagulation After PCI | COR: 1, LOE: B-R |
| PM-4 | P2Y12 Inhibitors With Fibrinolytic Therapy | COR: 1, LOE: C-LD |
| PM-5 | Aspirin in Patients Undergoing CABG | COR: 1, LOE: B-R; COR: 1, LOE: A |
| PM-6 | Lipid Management | COR: 1, LOE: A; COR:1, LOE: B-NR |
| PM-7 | Glycemic Control and CABG Surgery | COR: 1, LOE: B-R |
| PM-8 | Use of the IMA in CABG | COR: 1, LOE: B-NR |
| PM-9 | Patients With Diabetes and Multivessel Disease | COR: 1, LOE: A |
| PM-10 | Arterial Access for PCI | COR: 1, LOE: A |
| PM-11 | Non-Infarct Artery Revascularization in STEMI | COR: 1, LOE: A |
| PM-12 | Non-Infarct PCI in STEMI With Shock | COR: 3 Harm, LOE: B-R |
| PM-13 | Management of Ventricular Arrhythmias | COR: 1, LOE: B-NR |
| PM-14a | Cardiac Rehabilitation Referral From Inpatient Setting | COR: 1, LOE: A |
| PM-14b | Cardiac Rehabilitation Referral Outpatient Setting | COR: 1, LOE: A |

Quality and Structural Measures

| Measure No. | Measure Title/Description | COR/LOE |
|---------------------|--|-----------------------------------|
| Quality Measures | | |
| QM-1 | Shared Decision-Making and Informed Consent | COR: 1, LOE: C-LD |
| QM-2 | Periprocedural Hydration in Cardiovascular Angiography | COR: 1, LOE: B; COR: 1, LOE: C-LD |
| QM-3 | Smoking Cessation After Revascularization | COR: 1, LOE: A |
| QM-4 | Risk Assessment Before CABG | COR: 1, LOE: B-NR |
| QM-5 | Reduction of Atrial Fibrillation After CABG | COR: 1, LOE: B-R |
| Structural Measures | | |
| SM-1 | Preprocedural Assessment and the Heart Team | COR: 1, LOE: B-NR |
| SM-2 | Registry Participation | COR: 1, LOE: B-NR |

Summary

- 15 performance measures
- 5 quality measures
- 2 structural measures
- Measures were selected based on their importance for health, the strength of data supporting the recommendations, existing gaps in patient care, ease of implementation, and risk for unintended consequences.
- Implementation of this measure set by clinicians and health care facilities will enhance safe, cost-efficient, patient-centered, and culturally sensitive care for individual patients.

Revasc Performance Measures Publication

Citations and Links to Revasc Performance Measures Publication

AHA Journal - *Circulation: Cardiovascular Quality and Outcomes*

Dehmer GJ, Grines CL, Bakaeen FG, Beasley DL, Beckie TM, Boyd J, Cigarroa JE, Das S, Diekemper RL, Frampton J, Hess CN, Ijioma N, Lawton JS, Shah B, Sutton NR. 2023 AHA/ACC clinical performance and quality measures for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. *Circulation: Cardiovascular Quality and Outcomes*. 2023;16:e000121. doi:10.1161/HCQ.0000000000000121

<https://www.ahajournals.org/doi/10.1161/HCQ.0000000000000121>

ACC Journal - *Journal of the American College of Cardiology*

Dehmer GJ, Grines CL, Bakaeen FG, et al. 2023 AHA/ACC clinical performance and quality measures for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. *J Am Coll Cardiol*. Published online July 27, 2023.

<https://www.jacc.org/doi/10.1016/j.jacc.2023.03.409>